Immunomodulatory and antitumor effects of shilajit and glycine: Natural metabolic modulators targeting breast and liver cancer

doi:10.5306/wjco.v17.i5.119163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

(19)

(26)

(0)

(13)

(465)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. May 24, 2026; 17(5): 119163
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.119163

Full Size Figure Download Figure

Figure 6 Integrative mechanisms of shilajit and glycine in cancer therapy. NF-κB: Nuclear factor-kappa B; VEGF: Vascular endothelial growth factor; STAT3: Signal transducer and activator of transcription 3; MDSC: Myeloid-derived suppressor cell; ROS: Reactive oxygen species.

Citation: Basbrain TA, Zabermawi NM, Alrahimi JS, Zaher KA. Immunomodulatory and antitumor effects of shilajit and glycine: Natural metabolic modulators targeting breast and liver cancer. World J Clin Oncol 2026; 17(5): 119163
URL: https://www.wjgnet.com/2218-4333/full/v17/i5/119163.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i5.119163

Basbrain TA, Zabermawi NM, Alrahimi JS, Zaher KA. Immunomodulatory and antitumor effects of shilajit and glycine: Natural metabolic modulators targeting breast and liver cancer. World J Clin Oncol 2026; 17(5): 119163 [DOI: 10.5306/wjco.v17.i5.119163]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.